TABLE 2.

Reported human pharmacokinetic properties of FDA-approved top hits.

Sample name	Cmax (ng/ml)	MW (g/mol)	Cmax (µM)	Elimination T1/2	Dosing regimen	References
(+/-) -Fluoxetine	15–55	309.33	0.05–0.18	1–3 days	Single dose 40 mg PO	Eli Lilly and Company (1987)
Amiodarone hydrochloride	5,000–41,000	681.78	7.33–60.14	9–36 days	Single dose 5 mg/kg IV	Hospira (1995)
Amodiaquine dihydrochloride	32 ± 3	464.8	0.069	5.2 ± 1.7 h	Single dose 600 mg PO	Winstanley et al. (1987)
Chlorprothixene	430 ± 81	315.9	1.36	25.8 ± 13.6 h	Single dose 100 mg IV	Bagli et al. (1996)
Clemastine fumarate	0.577 ± 0.252	460	0.0013	21.3 ± 11.6 h	Single dose 1.34 mg PO	Schran et al. (1996)
Deserpidine	0.172	578.66	0.0003	42.9 ± 17.8 h	Single dose 0.25 mg PO	Zhang et al. (2009)
Duloxetine hydrochloride	110	333.88	0.33	6.96–14.9 h	60 mg BID PO	Knadler et al. (2011)
Imatinib	3,395 ± 2,409	493.6	6.88	10–18.9 h	Single dose 600 mg PO	Peng et al. (2005)
Loperamide hydrochloride	2	477	0.0042	9.1–14.4 h	Single dose 2 mg PO	Janssen Pharmaceutica Inc. (1998)
Maprotiline hydrochloride	25	313.87	0.080	45 h	Single dose 75 mg PO	Maguire et al. (1980)
a Methdilazine hydrochloride		332.9
Methotrimeprazine maleate	3.44	444.6	0.0077	10.8 h	Single dose 25 mg PO	AA Pharma Inc. (2012)
a Piperacetazine		410.6
Remdesivir	4,420	602.58	7.34	1.05 h	Single dose 225 mg IV	Humeniuk et al. (2020)

^aDiscontinued drugs. No PK data available.

C_max: maximum serum/plasma concentration; MW: molecular weight; Elimination T_1/2: elimination half life; PO: per os (oral dosing); IV: intravenous.